Overview

To Assess With Ezefeno Tab. in Patients With Dyslipidemia and T2DM

Status:
RECRUITING

Trial end date:
2027-02-01

Target enrollment:

Participant gender:

Summary

The goal of this Randomized controlled trials is to assess in the long term efficacy and safety of ezefeno. The primary endpoint are: * major adverse cardiovascular events within 48 months of the trial duration * microvascular events within 48 months of the trial duration

Phase:

Details

Lead Sponsor:

Korea University Anam Hospital

Treatments:

Ezetimibe
Fenofibrate